HEPATIC STEATOSIS AS DIABETES TYPE 2 PREDICTOR

被引:9
|
作者
Loureiro, Carolina [1 ]
Martinez-Aguayo, Alejandro [1 ]
Campino, Carmen [2 ]
Carvajal, Cristian [2 ]
Fardella, Carlos [2 ]
Garcia, Hernan [1 ]
机构
[1] Pontificia Univ Catolica Chile, Div Pediat, Unidad Endocrinol Pediat, Santiago 8330074, Chile
[2] Pontificia Univ Catolica Chile, Dept Endocrinol, Santiago 8330074, Chile
关键词
Non alcoholic fatty liver disease (NAFLD); Steatohepatitis; Alanine aminotransferase; Insulin resistance; Type; 2; diabetes; FATTY LIVER-DISEASE; INSULIN-RESISTANCE; ALANINE AMINOTRANSFERASE; OBESE ADOLESCENTS; ADIPOSE-TISSUE; CHILDREN; ADIPONECTIN; PREVALENCE; INTERLEUKIN-6; OVERWEIGHT;
D O I
10.3305/nh.2014.29.2.7098
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Non alcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance (IR) and increased type 2 diabetes (T2D). Alanine aminotransferase (ALT) is recognized as biochemical marker of NAFLD, currently used as screening for this disease. Objective: To estimate the associations between (ALT) with anthropometric variables, insulin resistance and inflamatory markers in pediatric population. Patients and Method: we studied 348 subjects (52.7% females), aged between 4.9 and 15.6 years. Blood samples for measuring: AST, ALT, glycaemia, insulin, lipid profile, hsCRP TNF-alpha, IL-6 and adiponectin. We calculate HOMA-IR, QUICKI y el HOMA-beta. The results are expressed are expressed as median interquartile range. Variables were log10 transformed before Pearson correlations analyze. Results: Serum ALT levels were positively associated with BMI-SDS (r = 0.335), waist/height ratio (r = 0.358), insulin (r = 0.33), HOMA-IR (r = 0.33), HOMA-beta (r = 0.26), TG/HDL-c (r = 0.2), hsCRP (r = 0.3); and a negative association with QUICKI (r = -0.25) and adiponectin (r = -0.113). Non-association with ALT, glycaemia, TNF-a and IL-6 was found. Conclusion: Our study demonstrated that ALT, but not AST, was significantly correlated with of insulin resistance and inflamatory markers, all of them recognized as risk parameters of pre diabetes stage. ALT should be part of the evaluation of all obesity children, mainly those with other cardiometabolic risk factors, since it could predict later development of T2DM. Further imaging studies are necessary to confirm fatty liver disease in this population.
引用
收藏
页码:350 / 358
页数:9
相关论文
共 50 条
  • [31] Association of hepatic steatosis with subclinical cardiac dysfunction in asymptomatic people with type 2 diabetes
    Yeo, J. L.
    Gulsin, G. S.
    Dattani, A.
    Brady, E. M.
    Bilak, J. M.
    Ayton, S. L.
    Moss, A. J.
    Pang, W.
    Boulos, S.
    House, M. J.
    St Pierre, T. G.
    McCann, G. P.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2406 - 2406
  • [32] Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes
    Lingvay, Ildiko
    Raskin, Philip
    Szczepaniak, Lidia S.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2007, 21 (03) : 137 - 142
  • [33] Steatosis and NASH in type 2 diabetes
    Hu, Mengyue
    Phan, Franck
    Bourron, Olivier
    Ferre, Pascal
    Foufelle, Fabienne
    BIOCHIMIE, 2017, 143 : 37 - 41
  • [34] Severity of hepatic steatosis is associated with atherosclerotic cardiovascular disease and type 2 diabetes mellitus
    Ayonrinde, Oyekoya
    Adams, Leon A.
    Mori, Trevor
    Melton, Phillip
    Olynyk, John
    Zelesco, Marilyn
    Mould, Andrea
    Fiori, James
    Beilin, Lawrence
    Dwivedi, Girish
    Sanfilippo, Frank
    Welman, Christopher
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 130 - 130
  • [35] Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study*
    Corbin, Karen D.
    Pittas, Anastassios G.
    Desouza, Cyrus
    Grdinovac, Kristine K.
    Herzig, Karl-Heinz
    Kashyap, Sangeeta R.
    Kim, Sun H.
    Nelson, Jason
    Rasouli, Neda
    Vickery, Ellen M.
    Knowler, William C.
    Pratley, Richard E.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2023, 37 (06)
  • [36] Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study
    Williamson, Rachel M.
    Price, Jackie F.
    Glancy, Stephen
    Perry, Elisa
    Nee, Lisa D.
    Hayes, Peter C.
    Frier, Brian M.
    Van Look, Liesbeth A. F.
    Johnston, Geoffrey I.
    Reynolds, Rebecca M.
    Strachan, Mark W. J.
    DIABETES CARE, 2011, 34 (05) : 1139 - 1144
  • [37] Effect of Insulin Versus Triple Oral Therapy on the Progression of Hepatic Steatosis in Type 2 Diabetes
    Lingvay, Ildiko
    Roe, Erin D.
    Duong, Jonathan
    Leonard, David
    Szczepaniak, Lidia S.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2012, 60 (07) : 1059 - 1063
  • [38] Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
    Kjeldsen, Sasha A. S.
    Thomsen, Mads N.
    Skytte, Mads J.
    Samkani, Amirsalar
    Richter, Michael M.
    Frystyk, Jan
    Magkos, Faidon
    Hansen, Elizaveta
    Thomsen, Henrik S.
    Holst, Jens J.
    Madsbad, Sten
    Haugaard, Steen B.
    Krarup, Thure
    Albrechtsen, Nicolai J. Wewer
    JOURNAL OF THE ENDOCRINE SOCIETY, 2023, 7 (11)
  • [39] The relationship between hepatic steatosis and skeletal muscle mass index in men with type 2 diabetes
    Hashimoto, Yoshitaka
    Osaka, Takafumi
    Fukuda, Takuya
    Tanaka, Muhei
    Yamazaki, Masahiro
    Fukui, Michiaki
    ENDOCRINE JOURNAL, 2016, 63 (10) : 877 - 884
  • [40] Activating Transcription Factor 3 Is a Targeted Molecule Linking Hepatic Steatosis To Type 2 Diabetes
    Kim, Won
    So, Young Ho
    Joo, Sae Kyung
    Jung, Yong Jin
    HEPATOLOGY, 2016, 64 : 773A - 773A